文献速递免疫规划妇幼与学校卫生

妊娠期接种Tdap疫苗与绒毛膜羊膜炎及相关婴儿结局的风险

Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes.
PubMed 文献 · Vaccine · 2023-04-26

该回顾性观察性队列研究纳入2016年10月至2018年9月8个VSD站点15-49岁单胎活产的孕妇118,211人,其中103,258人(87%)孕期接种Tdap疫苗,8,098人(7%)诊断为绒毛膜羊膜炎。调整后Tdap暴露组绒毛膜羊膜炎风险比为0.96(95%CI 0.90-1.03),与早产及不良婴儿结局无关;病历复核显示临床绒毛膜羊膜炎PPV为48%,组织学为59%,联合结局为81%。结论认为孕期Tdap暴露与绒毛膜羊膜炎、早产或不良婴儿结局无关。

要点

  • 孕期接种Tdap疫苗与绒毛膜羊膜炎风险无关(调整HR 0.96,95%CI 0.90-1.03)。
  • Tdap疫苗与早产及绒毛膜羊膜炎相关的不良婴儿结局均无关联。
  • ICD-10绒毛膜羊膜炎编码对临床绒毛膜羊膜炎特异性不足,PPV仅48%,为解读局限。

核心结论

  • 孕期Tdap疫苗暴露与绒毛膜羊膜炎、早产或不良婴儿结局无关。
  • ICD-10绒毛膜羊膜炎编码对临床绒毛膜羊膜炎缺乏特异性,应作为解读结果时的已知局限。

研究设计与样本

  • 回顾性观察性队列研究,纳入2016年10月至2018年9月8个Vaccine Safety Datalink(VSD)站点15-49岁单胎活产的孕妇118,211人。
  • 采用含时依协变量的Cox模型并应用稳定逆概率权重评估Tdap接种与绒毛膜羊膜炎及早产结局的关联。
  • 采用稳健方差泊松回归并应用稳定逆概率权重评估Tdap接种与不良婴儿结局的关联。
  • 对随机抽取的ICD-10-CM诊断绒毛膜羊膜炎患者进行病历复核,计算阳性预测值(PPV)。

主要发现

  • 118,211名孕妇中103,258人(87%)孕期接种Tdap疫苗,8,098人(7%)诊断为绒毛膜羊膜炎。
  • Tdap暴露组相比未暴露组,绒毛膜羊膜炎调整风险比为0.96(95%CI 0.90-1.03)。
  • Tdap疫苗与早产及绒毛膜羊膜炎相关的不良婴儿结局均无关联。
  • 对528名绒毛膜羊膜炎孕妇进行病历复核,临床绒毛膜羊膜炎( probable或possible clinical)PPV为48%,组织学绒毛膜羊膜炎PPV为59%。
  • 临床或组织学绒毛膜羊膜炎联合结局的PPV为81%。

关键数值与推荐

  • Tdap暴露组vs未暴露组绒毛膜羊膜炎调整HR 0.96(95%CI 0.90-1.03)。
  • 临床绒毛膜羊膜炎PPV 48%,组织学绒毛膜羊膜炎PPV 59%,联合结局PPV 81%。

临床怎么用

  • 孕期Tdap疫苗接种与绒毛膜羊膜炎、早产及不良婴儿结局无关。
  • 解读基于ICD-10编码的绒毛膜羊膜炎结果时,应认识到该编码对临床绒毛膜羊膜炎缺乏特异性这一局限。

局限性

  • ICD-10绒毛膜羊膜炎编码对临床绒毛膜羊膜炎缺乏特异性,应作为解读结果时的已知局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: An increased risk of chorioamnionitis in people receiving tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine during pregnancy has been reported. The importance of this association is unclear as additional study has not demonstrated increased adverse infant outcomes associated with Tdap vaccination in pregnancy. METHODS: We conducted a retrospective observational cohort study of pregnant people ages 15-49 years with singleton pregnancies ending in live birth who were members of 8 Vaccine Safety Datalink (VSD) sites during October 2016-September 2018. We used a time-dependent covariate Cox model with stabilized inverse probability weights applied to evaluate associations between Tdap vaccination during pregnancy and chorioamnionitis and preterm birth outcomes. We used Poisson regression with robust variance with stabilized inverse probability weights applied to evaluate the association of Tdap vaccination with adverse infant outcomes. We performed medical record reviews on a random sample of patients with ICD-10-CM-diagnosed chorioamnionitis to determine positive predictive values (PPV) of coded chorioamnionitisfor "probable clinical chorioamnionitis," "possible clinical chorioamnionitis," or "histologic chorioamnionitis." RESULTS: We included 118,211 pregnant people; 103,258 (87%) received Tdap vaccine during pregnancy; 8098 (7%) were diagnosed with chorioamnionitis. The adjusted hazard ratio for chorioamnionitis in the Tdap vaccine-exposed group compared to unexposed was 0.96 (95% CI 0.90-1.03). There was no association between Tdap vaccine and preterm birth or adverse infant outcomes associated with chorioamnionitis. Chart reviews were performed for 528 pregnant people with chorioamnionitis. The PPV for clinical (probable or possible clinical chorioamnionitis) was 48% and 59% for histologic chorioamnionitis. The PPV for the combined outcome of clinical or histologic chorioamnionitis was 81%. CONCLUSIONS AND RELEVANCE: Tdap vaccine exposure during pregnancy was not associated with chorioamnionitis, preterm birth, or adverse infant outcomes. ICD-10 codes for chorioamnionitis lack specificity for clinical chorioamnionitis and should be a recognized limitation when interpreting results.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Greenberg V, Vazquez-Benitez G, Kharbanda EO, et al. Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes. Vaccine. 2023. PMID: 37117057. doi:10.1016/j.vaccine.2023.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。